P400: Discordance in patient and physician perspectives and priorities in communication and management of ulcerative colitis: results of the European ulcerative colitis narrative survey
ECCO '19 Copenhagen
2019
P401: Association between induction vedolizumab drug levels and therapy outcome in inflammatory bowel disease
ECCO '19 Copenhagen
2019
P402: Systemic steroids vs. local acting steroids: Relative risk for corticosteroid-related adverse events
ECCO '19 Copenhagen
2019
P403: Intravenous iron infusion in inflammatory bowel disease: efficacy and ferro-economics
ECCO '19 Copenhagen
2019
P404: Stopping 5-aminosalicylates in Crohn’s disease patients starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts
ECCO '19 Copenhagen
2019
P405: Sustainability of biologic therapies is less in UC than CD patients independent of prior biologic experience
ECCO '19 Copenhagen
2019
P406: General health status in patients with moderate to severe ulcerative colitis receiving ustekinumab: results from the Phase 3 UNIFI induction and maintenance studies
ECCO '19 Copenhagen
2019
P407: Real-world safety of tofacitinib in inflammatory bowel diseases: a multi-centre study
ECCO '19 Copenhagen
2019
P408: Switching from infliximab originator to a biosimilar does not affect efficacy, pharmacokinetics and immunogenicity in paediatric patients with inflammatory bowel disease
ECCO '19 Copenhagen
2019
P409: Non-medical reverse switch between the originator infliximab and its biosimilar in patients with inflammatory bowel disease: clinical outcomes and therapeutic drug monitoring
ECCO '19 Copenhagen
2019
P410: Extraintestinal manifestations and quality of life in patients with ulcerative colitis: 1-year data from ICONIC
ECCO '19 Copenhagen
2019
P412: Efficacy and safety of additional autologous platelet-rich stroma in transanal mucosal advancement flap repair of complex cryptoglandular anal fistulas
ECCO '19 Copenhagen
2019
P413: A simple scoring tool predicts exposure–response relationship, onset of action, response to interval shortening, and surgical risk with vedolizumab therapy for Crohn’s disease
ECCO '19 Copenhagen
2019
P414: Ustekinumab endoscopic response at Week 16 is associated with early normalisation of faecal calprotectin after induction
ECCO '19 Copenhagen
2019
P415: Predictive factors of a subsequent ano-perineal abscess in patients with fistulising ano-perineal Crohn’s disease in remission
ECCO '19 Copenhagen
2019
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
ECCO '19 Copenhagen
2019
P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results
ECCO '19 Copenhagen
2019